In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

NEW YORK, Dec 2 (Reuters) - CVS Health (CVS.N), opens new tab will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements ...

CVS reached a settlement on Tuesday with the U.S. Attorney for the Southern District of New York for over $37.75 million after the retailer was accused of over-dispensing insulin pens to patients.

Austin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, the global Smart Insulin Pens Market was valued at $877.26 million in 2024 and is projected to reach $1818.89 million by 2032, ...

NEW YORK, Dec 2 (Reuters) - CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements from Medicare, Medicaid ...

CVS Health (CVS) has reached a settlement with the U.S. government, requiring the company to pay $37.76M to resolve claims that it overbilled government healthcare programs for insulin pens. The ...

The partnership is the first time Medtronic has integrated its insulin pumps with a sensor developed outside of the company.

Sarah Jividen, RN, BSN, is a trained neuro/trauma, and emergency room nurse turned healthcare writer. As a journalism major, she combined her love for writing with her passion for high-level patient ...